Followers | 145 |
Posts | 27561 |
Boards Moderated | 3 |
Alias Born | 02/07/2004 |
Wednesday, March 03, 2021 8:48:43 AM
https://finance.yahoo.com/news/national-institute-health-care-excellence-133000690.html
Experts outline potential for improved stroke patient outcomes, cost effectiveness through use of the ReStore device in the rehabilitation setting
MARLBOROUGH, Mass., March 3, 2021 /PRNewswire/ -- ReWalk Robotics, Ltd. (Nasdaq: RWLK) ("ReWalk" or the "Company"), a manufacturer of robotic medical devices for individuals with lower limb disabilities, today announced its ReStore Soft Exo-Suit was the subject of a recent Medtech Innovation Briefing (MIB) by the UK's National Institute for Health and Care Excellence (NICE). These briefings are designed to support National Health Services (NHS) and social care commissioners and staff who are considering using new medical devices and other medical or diagnostic technologies.
The briefing, titled "ReStore Soft Exo-Suit for gait rehabilitation" includes a description of the ReStore device, how it's used and why the technology is innovative for the treatment of patients during post-stroke gait training. The MIB also outlines a pathway to care using the technology and how much it costs.
"Publication of the NICE briefing is a critical step in achieving broad adoption of the ReStore Soft Exo-Suit for use in rehabilitation clinics throughout the United Kingdom," said ReWalk CEO Larry Jasinski. "These briefings are vital in informing the clinical teams who rely on NICE to make sure they are aware of the latest technologies that can help patients and deliver quality care. We are confident the support of NICE will help us to bring the ReStore to more patients in need across the UK."
Notably, the MIBs include expert commentary, to help inform NHS on the use of the device in the care setting. In the ReStore briefing, experts agreed that ReStore could improve outcomes by reducing falls and improving a user's balance and confidence. Experts also suggested that ReStore could reduce the number of staff needed in therapy sessions because fewer people would be needed to assist patients.
"Our initial impression is that the ReStore has the potential to influence neuro-plasticity, 're-wiring' of the nervous system, for a range of patients and presentations," said Tom McGregor, clinical lead for Hull and East Yorkshire at MOTIONrehab. "By using the ReStore patients have better gait biomechanics, which in turn is resulting in increased walking distances, faster walking speeds and greater confidence to walk. We're using ReStore as a therapy tool in clinic to optimize our treatment sessions. The clients that have tried it so far have reacted really well, so the plan is to utilize it on successive sessions over the coming weeks and months," he added.
While the experts agreed that the ReStore is likely to cost more than the current standard of care, one of the commentators noted the case for cost effectiveness could be proven with evidence the ReStore improved neuromuscular recovery more than standard care, and lowered resource impact.
The ReStore system is comprised of a soft, garment-like design which connects to a lightweight waist pack and mechanical cables that help lift the patient's affected leg in synchronized timing with their natural walking pattern. The system provides targeted assistance to the patient during forward propulsion (plantarflexion) and ground clearance (dorsiflexion), two key phases of the gait cycle. Real-time data from sensors in the shoes and on the affected leg are used to adjust the mechanical assistance to match the user's natural gait and to enhance propulsion symmetry. This provides the physical therapists with extensive data to inform strategies to optimize a patient's treatment and progress using real-time analytics.
For more information, please visit rewalk.com.
Recent RWLK News
- Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend] • Edgar (US Regulatory) • 04/29/2024 12:30:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/22/2024 08:16:29 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 04/22/2024 08:15:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/19/2024 12:46:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/04/2024 01:01:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/03/2024 11:34:09 AM
- VA STAND Act introduced in the United States Senate • GlobeNewswire Inc. • 03/22/2024 12:30:00 PM
- Lifeward Announces Reverse Share Split • GlobeNewswire Inc. • 03/13/2024 03:45:17 PM
- ReStore Exo-Suit Publications Demonstrate Improved Walking Outcomes Versus Conventional Stroke Therapy • GlobeNewswire Inc. • 03/08/2024 01:30:00 PM
- Lifeward announces the Centers for Medicare & Medicaid Services (“CMS”) is deferring its final decision on the payment rate for personal exoskeletons so that more recent claims information on the current, more advanced ReWalk Personal Exoskeleton may b • GlobeNewswire Inc. • 03/01/2024 01:45:11 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/27/2024 02:15:46 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/27/2024 01:15:25 PM
- Lifeward Reports Fourth Quarter and Full Year 2023 Financial Results • GlobeNewswire Inc. • 02/27/2024 01:00:07 PM
- Lifeward to Report Fourth Quarter and Fiscal Year-End 2023 Financial Results on February 27, 2024 • GlobeNewswire Inc. • 02/20/2024 01:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/30/2024 09:15:24 PM
- ReWalk Robotics Transforms Company Identity, Rebrands as Lifeward • GlobeNewswire Inc. • 01/29/2024 01:00:00 PM
- ReWalk Robotics Expands Direct Sales Coverage to Canada • GlobeNewswire Inc. • 01/12/2024 01:30:00 PM
- ReWalk Robotics Ltd. to Present at Sidoti Virtual Investor Conference on January 17 • GlobeNewswire Inc. • 01/11/2024 10:00:06 PM
- First ReWalk Personal Exoskeleton Claim Paid by Medicare • GlobeNewswire Inc. • 01/05/2024 01:00:00 PM
- ReWalk Robotics CEO Issues Year-End 2023 Open Letter to Shareholders and Provides 2024 Commercial and Operational Priorities • GlobeNewswire Inc. • 01/04/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/19/2023 09:04:05 PM
- ReWalk Robotics Presents on Personal Exoskeleton Pricing at Medicare Public Meeting • GlobeNewswire Inc. • 11/30/2023 09:45:00 PM
- ReWalk Robotics Demonstrates AI Autonomous Decision Making in Next Generation Exoskeleton Prototype • GlobeNewswire Inc. • 11/28/2023 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/21/2023 09:37:18 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 11/20/2023 11:39:22 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM